The clinical efficacy of tiagabine

Reviews in Contemporary Pharmacotherapy

Volumn 12, Issue 5, 2002, Pages 235-250

  Gaitatzis, Athanasios ^a   Patsalos, Philip N ^a   Sander, Josemir W A S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; ZONISAMIDE;

ADOLESCENT; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EPILEPSY; HUMAN; META ANALYSIS; REVIEW; TREATMENT OUTCOME;

EID: 0036346904     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Monotherapy antiepileptic drug trials in patients undergoing presurgical assessment: Methodological problems and possibilities
2. Tiagabine in the treatment of infantile spasms
3. Open study with tiagabine in partial epilepsy
4. Efficacy and tolerability of tiagabine: Results of an add-on study with refractory partial seizures
5. The epidemiology of epilepsy: The size of the problem
6. International experience with tiagabine add-on therapy
7. Tiagabine monotherapy in adults and children in a long-term study
8. Monotherapy with tiagabine in an open-label study of partial seizures
9. Adjunctive tiagabine compared with phenytoin and carbamazepine in the multicenter, double-blind trial of complex partial seizures
10. Long-term treatment of children with tiagabine
11. Long-term treatment of partial seizures with tiagabine in children
12. Long-term trial of tiagabine (Gabitril®) for partial seizures in children
13. Use of the new anti-epileptic drugs (lamotrigine, oxcarbazepine, topiramate, tiagabine) in children with therapeutically refractory seizures
14. Tiagabine pharmacology in profile
15. Prognosis of epilepsy: A review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study
16. Tiagabine adjunctive therapy in children and adults with refractory partial epilepsy
17. General principles: Compliance with antiepileptic drug therapy
18. Efficacy and adverse effects of gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide and vagal nerve stimulation
19. Tiagabine: Phase II study of efficacy and safety in adjunctive treatment of partial seizures
20. Tiagabine efficacy and safety in adjunctive treatment of partial seizures
21. Utility of tiagabine (TGB) in epilepsy patients with glial tumors
22. Patients with refractory seizures
23. Tiagabine as a model of add-on to a standard AED
24. Tiagabine as a good substitute for vigabatrin for controlled epileptic patients
25. New antiepileptic drugs
26. Long-term safety and efficacy evaluation of patients with partial seizures treated with tiagabine in two open extension studies
27. Long-term safety and efficacy of tiagabine in an open-label study of patients with epilepsy
28. Reduction in concomitant AED use with tiagabine in a long-term clinical study
29. Long-term extension study of tiagabine: Safety and efficacy in patients with partial seizures
30. Safety of long term treatment with tiagabine
31. Tiagabine treatment in pharmacoresistant focal epilepsy
32. Critical interpretation of antiepileptic drug trials: Beyond regulatory trials
33. Postmarketing experience with tiagabine
34. Comparison of patients who became seizure free taking lamotrigine, topamax, or tiagabine: Data from the PADS study group
35. Tiagabine monotherapy in chronic partial epilepsy
36. Tiagabine monotherapy in chronic partial epilepsy
37. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures
38. Slow versus fast drug switch from established AED to tiagabine monotherapy
39. Tiagabine monotherapy in chronic partial epilepsy
40. Which patients respond to tiagabine monotherapy?
41. Tiagabine treatment of psychiatric disorders
42. Tiagabine in the management of post-encephalitic epilepsy and impulse control disorder
43. Efficacy of tiagabine and topiramate as add-on therapy in drug resistant simple or complex partial and secondary generalised seizures
44. Beneficial effects of tiagabine in patients with psychiatric history
45. Efficacy and tolerability of tiagabine in infantile spasms
46. Summary of open-label long-term trials with tiagabine as adjunctive treatment of patients with epilepsy
47. Tiagabine
48. A review of lamotrigine, tiagabine, and topiramate in the institutionalized population with epilepsy: What seems to be working
49. Gabitril shows improvement in refractory partial seizure patients who have extratemporal foci
50. An open label trial on the efficacy of tiagabine as add on therapy in poorly controlled seizures
51. New drug treatments for epilepsy
52. New antiepileptic drugs: A systematic review of their efficacy and tolerability
53. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
54. The pharmacology and pharmacokinetics of vigabatrin
55. Use of tiagabine as long-term therapy for complex partial seizures in adolescents
56. Meta-analysis of adjunctive tiagabine efficacy and safety in adolescents in controlled studies
57. Antiepileptic drugs as a cause of worsening seizures
58. Tiagabine in refractory epilepsy: An open, add-on study with a follow-up of 2 years
59. Open-label study of the safety and efficacy of long-term tiagabine in patients with epilepsy
60. Open treatment with tiagabine and conversion to monotherapy of patients with uncontrolled partial and generalized seizures
61. Double-blind three-dose parallel placebo-controlled efficacy of tiagabine in partial seizures
62. Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial
63. Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures
64. Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures
65. Tiagabine therapy for complex partial seizures. A dose-frequency study
66. Tiagabine as monotherapy for chronic temporal or non-temporal lobe partial epilepsy
67. New drugs for epilepsy
68. Epidemiology of the epilepsies
69. Natural history and prognosis
70. Safety and efficacy of tiagabine HCl monotherapy in the treatment of partial seizures: High dose versus low dose
71. Maintenace of tiagabine therapy for complex partial seizures
72. Long-term use of tiagabine for partial seizures
73. Open-label dosage and tolerability of tiagabine monotherapy in patients with refractory complex partial seizures
74. Tiagabine in the treatment of epilepsy - A clinical review with a guide for the prescribing physician
75. Tiagabine
76. Tiagabine in glial tumors
77. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy
78. Tiagabine adjunctive therapy in children with refractory epilepsy: A single-blind dose escalating study
79. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial
80. Postmarketing experience with tiagabine
81. Tiagabine in drug-resistant epilepsy in children: Preliminary study
82. The use of tiagabine in pediatric patients with intractable epilepsy